Kinnate Biopharma Inc. - Annual Report: 2020 (Form 10-K)

●

being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure in our periodic reports;

●

not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (Sarbanes-Oxley Act);

●

not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements;

●

reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and

●

exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not previously approved.

●

establish a classified board of directors so that not all members of our board are elected at one time;

●

permit only the board of directors to establish the number of directors and fill vacancies on the board;

●

provide that directors may only be removed “for cause” and only with the approval of two-thirds of our stockholders;

●

authorize the issuance of “blank check” preferred stock that our board could use to implement a stockholder rights plan (also known as a “poison pill”);

●

eliminate the ability of our stockholders to call special meetings of stockholders;

●

prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;

●

prohibit cumulative voting;

●

authorize our board of directors to amend the bylaws;

●

establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings; and

●

require a super-majority vote of stockholders to amend some provisions described above.

●

any derivative action or proceeding brought on our behalf;

●

any action asserting a claim of breach of fiduciary duty;

●

any action asserting a claim against us arising under the DGCL, our amended- and restated certificate of incorporation or our amended and restated bylaws; and

●

any action asserting a claim against us that is governed by the internal-affairs doctrine.

Item 1B.

Unresolved Staff Comments.

Item 2.

Properties.

Item 3.

Legal Proceedings.

Item 4.

Mine Safety Disclosures.

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Item 6.

Selected Financial Data.

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

●

advance our RAF and FGFR programs from discovery and preclinical development into and through clinical development;

●

advance the development of our other small molecule research programs, including our CDK12 inhibitor;

●

expand our pipeline of product candidates through our own product discovery and development efforts;

●

seek to discover and develop additional product candidates;

●

seek regulatory approvals for any product candidates that successfully complete clinical trials;

●

establish a sales, marketing and distribution infrastructure to commercialize any approved product candidates and related additional commercial manufacturing costs;

●

implement operational, financial and management systems;

●

attract, hire and retain additional clinical, scientific, management and administrative personnel;

●

maintain, expand, protect and enforce our intellectual property portfolio, including patents, trade secrets and know how; and

●

operate as a public company.

●

expenses incurred in connection with the discovery and preclinical development of our product candidates, including under agreements with third parties, such as consultants and CROs;

●

the cost of manufacturing compounds for use in our preclinical studies, including under agreements with third parties, such as consultants and CMOs; and

●

costs associated with consultants for chemistry, manufacturing and controls (CMC) development, regulatory, statistics and other services.

●

for 2020, employee-related expenses, including salaries and benefits, travel and stock-based compensation expense for employees engaged in research and development functions; and

●

for 2019, research and development services provided by FSC and stock-based compensation expense.

●

the timing and progress of preclinical and clinical development activities;

●

the number and scope of preclinical and clinical programs we decide to pursue;

●

our ability to maintain our current research and development programs and to establish new ones;

●

establishing an appropriate safety profile with IND-enabling toxicology studies;

●

successful patient enrollment in, and the initiation and completion of, clinical trials;

●

per subject trial costs;

●

the number of trials required for regulatory approval;

●

the countries in which the trials are conducted;

●

the length of time required to enroll eligible subjects and initial clinical trials;

●

the number of subjects that participate in the trials;

●

the drop-out and discontinuation rate of subjects;

●

potential additional safety monitoring requested by regulatory authorities;

●

the duration of subject participation in the trials and follow-up;

●

the successful completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to applicable regulatory authorities;

●

the receipt of regulatory approvals from applicable regulatory authorities;

●

the timing, receipt and terms of any marketing approvals and post-marketing approval commitments from applicable regulatory authorities;

●

the extent to which we establish collaborations, strategic partnerships or other strategic arrangements with third parties, if any, and the performance of any such third party;

●

obtaining and retaining research and development personnel;

●

establishing commercial manufacturing capabilities or making arrangements with CMOs;

●

development and timely delivery of commercial-grade drug formulations that can be used in our planned clinical trials and for commercial launch; and

●

obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights.

		Years Ended December 31,
		2020				2019
		(in thousands)
Operating expenses:
Research and development (includes related party amounts of $0 and $2,301, respectively)		$	29,237			$	8,955
General and administrative (includes related party amounts of $92 and $2,609, respectively)			6,764				3,057
Total operating expenses			36,001				12,012
Loss from operations			(36,001	)			(12,012	)
Other income:
Interest income			245				43
Other (expense) income, net			(5	)			-
Total other income			240				43
Net loss		$	(35,761	)		$	(11,969	)

		Years Ended December 31,
		2020				2019
		(in thousands)
External expenses:
Lead programs		$	18,800			$	4,500
Other programs and other unallocated costs			4,346				2,120
Total external expenses			23,146				6,620
Internal expenses			6,091				2,335
Total research and development expenses		$	29,237			$	8,955

●

advance our RAF and FGFR programs from discovery and preclinical development into and through clinical development;

●

advance the development of our other small molecule research programs, including our CDK12 inhibitor;

●

expand our pipeline of product candidates through our own product discovery and development efforts;

●

seek to discover and develop additional product candidates;

●

seek regulatory approvals for any product candidates that successfully complete clinical trials;

●

establish a sales, marketing and distribution infrastructure to commercialize any approved product candidates and related additional commercial manufacturing costs;

●

implement operational, financial and management systems;

●

attract, hire and retain additional clinical, scientific, management and administrative personnel;

●

maintain, expand, protect and enforce our intellectual property portfolio, including patents, trade secrets and know how; and

●

operate as a public company.

●

the scope, timing, progress, results and costs of researching and developing our product candidates, and conducting preclinical studies and clinical trials;

●

the scope, timing, progress, results and costs of researching and developing other product candidates that we may pursue;

●

the costs, timing and outcome of regulatory review of our product candidates;

●

the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;

●

the costs of manufacturing commercial-grade products and sufficient inventory to support commercial launch;

●

the revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval;

●

the cost and timing of attracting, hiring and retaining skilled personnel to support our operations and continued growth;

●

the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;

●

our ability to establish and maintain collaborations, strategic partnerships or marketing, distribution, licensing or other strategic arrangements with third parties on favorable terms, if at all;

●

the extent to which we acquire or in-license other product candidates and technologies, if any;

●

the timing, receipt and amount of sales of, or milestone payments related to or royalties on, our current or future product candidates, if any; and

●

the costs associated with operating as a public company.

		Years Ended December 31,
		2020				2019
		(in thousands)
Net cash used in operating activities		$	(30,181	)		$	(10,526	)
Net cash used in investing activities			(31,709	)			-
Net cash provided by financing activities			350,899				79,980
Net increase in cash and cash equivalents		$	289,009			$	69,454

●

Fair Value of Common Stock-Prior to our initial public offering, the estimated fair value of our common stock was determined by our board of directors as of the date of each option grant, with input from management, considering our most recently available third-party valuation of our common stock as well as our board of directors’ assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent third-party valuation to the date of the grant.  Since the completion of our initial public offering, the fair value of each share of common stock underlying stock option grants is based on the closing price of our common stock on the Nasdaq Global Select Market as reported on the date of grant.

●

Expected Term-We have opted to use the “simplified method” for estimating the expected term of options, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option, which is generally 10 years.

●

Expected Volatility-Due to our limited operating history and a lack of company-specific historical and implied volatility data, we have based our estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the stock-based awards. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available.

●

Risk-Free Interest Rate-The risk-free interest rates used are based on the U.S. Treasury yield in effect at the time of grant for zero-coupon U.S. treasury notes with maturities approximately equal to the expected term of the stock options.

●

Expected Dividend-To date, we have not issued any dividends and do not expect to issue dividends over the life of the options and therefore have estimated the dividend yield to be zero.

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk.

Item 8.

Financial Statements and Supplementary Data

	Page
Report of Independent Registered Public Accounting Firm	110
Balance Sheets as of December 31, 2020 and 2019	111
Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2020 and 2019	112
Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) for the Years Ended December 31, 2020 and 2019	113
Statements of Cash Flows for the Years Ended December 31, 2020 and 2019	114
Notes to Financial Statements	115

		December 31,
		2020				2019
Assets
Current assets:
Cash and cash equivalents		$	365,462			$	76,453
Short-term investments			31,398				-
Related party receivables, net (See Note 9)			-				973
Prepaid expenses and other current assets			3,343				25
Total current assets			400,203				77,451
Property and equipment, net			368				154
Total assets		$	400,571			$	77,605
Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)
Current liabilities:
Accounts payable		$	3,940			$	956
Accrued expenses			3,364				989
Total current liabilities			7,304				1,945
Commitments and contingencies (See Note 11)
Convertible preferred stock:
Series A convertible preferred stock, $0.0001 par value;
0 and 7,762,733 shares authorized at December 31, 2020 and 2019, respectively;
0 and 7,762,727 shares issued and outstanding at December 31, 2020 and
2019, respectively; aggregate liquidation preference of $0 and $19,167 at
December 31, 2020 and 2019, respectively			-				18,942
Series B convertible preferred stock, $0.0001 par value;
0 and 9,705,185 share authorized at December 31, 2020 and 2019, respectively;
0 and 9,705,182 shares issued and outstanding at December 31, 2020 and
2019, respectively; aggregate liquidation preference of $0 and $74,500 at
December 31, 2020 and 2019, respectively			-				74,204
Stockholders’ equity (deficit):
Preferred stock, $0.0001 par value; 200,000,000 and 0 shares authorized
at December 31, 2020 and 2019, respectively; 0 shares outstanding
at December 31, 2020 and 2019, respectively			-				-
Common stock, $0.0001 par value; 1,000,000,000 and 26,914,696
shares authorized at December 31, 2020 and 2019, respectively;
43,477,439 and 3,665,020 shares issued and outstanding at
December 31, 2020 and 2019, respectively			4				-
Additional paid-in capital			446,601				82
Accumulated other comprehensive loss			(9	)			-
Accumulated deficit			(53,329	)			(17,568	)
Total stockholders’ equity (deficit)			393,267				(17,486	)
Total liabilities, convertible preferred stock and stockholders’ equity (deficit)		$	400,571			$	77,605

		Years Ended December 31,
		2020				2019
Operating expenses:
Research and development (includes related party amounts of $0 and $2,301, respectively)		$	29,237			$	8,955
General and administrative (includes related party amounts of $92 and $2,609, respectively)			6,764				3,057
Total operating expenses			36,001				12,012
Loss from operations			(36,001	)			(12,012	)
Other income:
Interest income			245				43
Other (expense) income, net			(5	)			-
Total other income			240				43
Net loss			(35,761	)			(11,969	)
Gain on extinguishment of Series A convertible preferred stock			-				2,031
Net loss attributable to common stockholders		$	(35,761	)		$	(9,938	)
Unrealized loss on short-term investments			(9	)			-
Comprehensive loss		$	(35,770	)		$	(9,938	)
Weighted-average shares outstanding, basic and diluted			6,767,591				3,659,456
Net loss attributable to common stockholders per share, basic and diluted		$	(5.28	)		$	(2.72	)

		Years Ended December 31,
		2020				2019
Cash flows from operating activities:
Net loss		$	(35,761	)		$	(11,969	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense			2,478				39
Depreciation			83				-
Amorization/accretion on short-term investments			5				-
Changes in operating assets and liabilities:
Related party receivables, net			973				(49	)
Prepaid expenses and other current assets			(3,318	)			(25	)
Accounts payable and accrued expenses			5,359				1,478
Net cash used in operating activities			(30,181	)			(10,526	)
Cash flows from investing activities:
Purchases of short-term investments			(31,412	)			-
Purchases of property and equipment			(297	)			-
Net cash used in investing activities			(31,709	)			-
Cash flows from financing activities:
Proceeds from issuance of common stock in initial public offering, net of issuance costs			253,314				-
Proceeds from issuance of Series A convertible preferred stock, net of issuance costs			-				5,775
Proceeds from issuance of Series B convertible preferred stock, net of issuance costs			(17	)			74,204
Proceeds from issuance of Series C convertible preferred stock, net of issuance costs			97,707				-
(Payments) proceeds upon stock option exercises, net of shares acquired upon forfeiture			(105	)			1
Net cash provided by financing activities			350,899				79,980
Net increase in cash and cash equivalents			289,009				69,454
Cash and cash equivalents at the beginning of the period			76,453				6,999
Cash and cash equivalents at the end of the year		$	365,462			$	76,453
Supplemental non-cash investing and financing activity:
Deferred offering costs included in accounts payable and accrued expenses		$	149			$	-
Property and equipment included in related party receivables, net		$	-			$	154

1)	Organization and Basis of Presentation

a)	Organization and Nature of Operations

b)	Basis of Presentation

c)	Initial Public Offering

2)	Summary of Significant Accounting Policies

a)	Use of Estimates

b)	Concentration of Credit Risk

c)	Fair Value of Financials Instruments

d)	Cash and Cash Equivalents

e)	Investments

f)	Net Property and Equipment

	Estimated Useful
	Lives (in years)
Furniture and fixtures	3-10
Computers and equipment	3-5
Computer software	3-5

g)	Impairment of Property and Equipment

h)	Research and Development

i)	Commitments and Contingencies

j)	Income Taxes

k)	Stock-Based Compensation

m)	Comprehensive Loss

n)	Net Loss Per Share

		Years Ended December 31,
		2020				2019
Numerator
Net loss		$	(35,761	)		$	(11,969	)
Gain on extinguishment of Series A convertible preferred stock			-				2,031
Net loss attributable to common stockholders		$	(35,761	)		$	(9,938	)
Denominator
Weighted-average shares outstanding used in computing net loss per share, basic and diluted			6,767,591				3,659,456
Net loss attributable to common stockholders per share, basic and diluted		$	(5.28	)		$	(2.72	)

		As of December 31,
		2020				2019
Options to purchase common stock			6,265,409				1,385,304
Convertible preferred stock			-				17,467,909
Total			6,265,409				18,853,213

o)	Recently Issued Accounting Standards

3)	Property and Equipment, Net

		December 31,
		2020				2019
Furniture and fixtures		$	72			$	72
Computers and equipment			275				48
Computer software			104				34
Property and equipment			451				154
Less accumulated depreciation			(83	)			-
Property and equipment, net		$	368			$	154

4)	Accrued Expenses

		December 31,
		2020				2019
Accrued research and development		$	1,580			$	681
Accrued compensation			1,388				-
Accrued legal fees			288				217
Other accruals			108				91
Total		$	3,364			$	989

5)	Investments

		December 31, 2020
		Amortized				Unrealized				Unrealized				Estimated
		Cost				Gains				Losses				Fair Value
Corporate debt securities		$	20,327			$	-			$	(9	)		$	20,318
Commerical paper			11,080				-				-				11,080
Total		$	31,407			$	-			$	(9	)		$	31,398

6)	Fair Value Measurements

Level 1:

Observable inputs such as quoted prices in active markets;

Level 2:

Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

Level 3:

Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

		Fair Value Measurements at December 31, 2020 Using:
		Level 1				Level 2				Level 3				Total
Money market funds		$	364,461			$	-			$	-			$	364,461
Corporate debt securities			-				20,318				-				20,318
Commerical paper			-				11,080				-				11,080
Total cash equivalents and short-term investments		$	364,461			$	31,398			$	-			$	395,859

		Fair Value Measurements at December 31, 2019 Using:
		Level 1				Level 2				Level 3				Total
Money market funds		$	75,453			$	-			$	-			$	75,453
Corporate debt securities			-				-				-				-
Commerical paper			-				-				-				-
Total cash equivalents and short-term investments		$	75,453			$	-			$	-			$	75,453

7)	Stockholders’ Equity

a)	Convertible Preferred Stock

b)	Common Stock

		As of December 31,
		2020				2019
Convertible preferred stock			-				17,467,909
Common stock options granted and outstanding			6,265,409				1,385,304
Common stock reserved for future option grants			5,619,735				3,114,593
Total common stock reserved for future issuance			11,885,144				21,967,806

8)	Equity Incentive Plans and Stock-Based Compensation

a)	Equity Incentive Plans

		Options				Weighted- Average Exercise Price				Weighted- Average Remaining Contractual Term (in years)				Aggregate Intrinsic Value (in thousands)
Outstanding at January 1, 2020			1,385,304			$	0.19				8.6
Granted			5,853,886				4.39				9.4
Forfeited			(693,000	)			0.17				7.5
Exercised			(280,781	)			0.42				7.8
Outstanding at December 31, 2020			6,265,409			$	4.12				9.3			$	223,454
Exercisable at December 31, 2020			508,488			$	1.77				8.5			$	19,327

b)	Employee Stock Purchase Plan

c)	Stock-Based Compensation Expense

		Years Ended December 31,
		2020				2019
Expected term (in years)			6 - 7				10
Expected volatility			88% - 93	%			96% - 99	%
Risk-free interest rate			0.37% - 1.57	%			1.80% - 2.64	%
Expected dividend			0	%			0	%

		Year Ended December 31, 2020
Expected term (in years)			0.41
Expected volatility			50.7	%
Risk-free interest rate			0.09	%
Expected dividend			0	%

9)	Related Party Transactions

a)	Management Service Agreement with Fount Therapeutics, LLC and Fount Service Corp.

		Year Ended December 31,
		2020				2019
FTL included in research and development		$	-			$	-
FTL included in general and administrative			80				841
Total FTL related party expense			80				841
FSC included in research and development			-				2,301
FSC included in general and administrative			12				1,768
Total FSC related party expense			12				4,069
Total related party expenses		$	92			$	4,910

		As of December 31,
		2020				2019
FTL related party receivables		$	-			$	250
FTL related party payables			-				(20	)
FTL related party receivables, net			-				230
FSC related party receivables			-				2,283
FSC related party payables			-				(1,540	)
FSC related party receivables, net			-				743
Total related party receivables, net		$	-			$	973

b)	Management Services Agreement with Subveho, LLC

10)	Income Taxes

		Year Ended
		2020				2019
Income taxes computed at the statutory rate		$	(7,510	)		$	(2,513	)
State income taxes, net of federal benefit			-				(825	)
Permanent items			4				25
Stock-based compensation			102				2
Other			(36	)
Change in valuation allowance			7,440				3,311
Provision for income taxes		$	-			$	-

		As of December 31,
		2020				2019
Deferred tax assets:
Net operating loss carryforward		$	12,304			$	5,404
Stock-based compensation			264				6
Accrued compensation			292				-
Other, net			23				31
Gross deferred tax assets:			12,883				5,441
Less valuation allowance			(12,883	)			(5,441	)
Total deferred tax assets			-				-
Deferred tax liabilities:
Fixed assets			-				-
Net deferred tax assets		$	-			$	-

11)	Commitments and Contingencies

12)	Employee Benefit Plan

13)	Subsequent Events

Item 9.

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.

Item 9A.

Controls and Procedures.

Item 9B.

Other Information.

Item 10.

Directors, Executive Officers and Corporate Governance.

Item 11.

Executive Compensation.

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

Item 13.

Certain Relationships and Related Transactions, and Director Independence.

Item 14.

Principal Accounting Fees and Services.

Item 15.

Exhibits, Financial Statement Schedules.

Item 16.

Form 10-K Summary.

				Incorporated by Reference
Exhibit Number		Exhibit Description		Form		File No.		Exhibit		Filing Date
3.1		Amended and Restated Certificate of Incorporation of the Registrant.		8-K		001-39743		3.1		December 8, 2020
3.2		Amended and Restated Bylaws of the Registrant.		8-K		001-39743		3.2		December 8, 2020
4.1		Amended and Restated Investors’ Rights Agreement by and among the Registrant and certain of its stockholders, dated August 24, 2020.		S-1		333-250086		4.1		November 13, 2020
4.2		Specimen common stock certificate of the Registrant.		S-1/A		333-250086		4.2		November 30, 2020
4.3		Description of Securities
10.1+		Form of Indemnification Agreement between the Registrant and each of its directors and executive officers.		S-1		333-250086		10.1		November 13, 2020
10.2+		2018 Equity Incentive Plan, as amended, and forms of agreement thereunder.		S-1		333-250086		10.2		November 13, 2020
10.3+		2020 Equity Incentive Plan and forms of agreements thereunder.		S-1/A		333-250086		10.3		November 30, 2020
10.4+		2020 Employee Stock Purchase Plan and forms of agreements thereunder.		S-1/A		333-250086		10.4		November 30, 2020
10.5+		Employment Letter between the Registrant and Nima Farzan.		S-1		333-250086		10.5		November 13, 2020
10.6+		Employment Letter between the Registrant and Mark Meltz.		S-1		333-250086		10.6		November 13, 2020
10.7+		Employment Letter between the Registrant and Eric Murphy, Ph.D.		S-1		333-250086		10.7		November 13, 2020
10.8+		Employment Letter between the Registrant and Richard Williams, MBBS, Ph.D.		S-1		333-250086		10.8		November 13, 2020
10.9+		Executive Incentive Compensation Plan.		S-1		333-250086		10.9		November 13, 2020
10.10+		Change in Control and Severance Agreement between the Registrant and Nima Farzan.		S-1		333-250086		10.10		November 13, 2020
10.11+		Change in Control and Severance Agreement between the Registrant and Mark Meltz.		S-1		333-250086		10.11		November 13, 2020
10.12+		Change in Control and Severance Agreement between the Registrant and Eric Murphy, Ph.D.		S-1		333-250086		10.12		November 13, 2020
10.13+		Change in Control and Severance Agreement between the Registrant and Richard Williams, MBBS, Ph.D.		S-1		333-250086		10.13		November 13, 2020
10.14		Outside Director Compensation Policy.		S-1/A		333-250086		10.14		November 30, 2020
10.15		Office Lease between the Registrant and Realty Income Properties 14, LLC, dated May 2, 2018, as amended by Amendment Number One dated May 5, 2020 and Amendment Number Two dated August 26, 2020, and the consent and assignment related thereto.		S-1		333-250086		10.15		November 13, 2020
10.16		Amendment Number Three to Office Lease between the Registrant and Realty Income Properties 14, LLC, dated November 16, 2020.		S-1/A		333-250086		10.16		November 30, 2020

23.1		Consent of KPMG LLP, Independent Registered Public Accounting Firm.
24.1		Power of Attorney (reference is made to the signature page hereto).
31.1		Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 †		Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 †		Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

	Kinnate Biopharma Inc.
Date: March 29, 2021	By:	/s/ Nima Farzan
		Nima Farzan
		President and Chief Executive Officer

Signature		Title		Date
/s/ Nima Farzan		President, Chief Executive Officer and Director (Principal Executive Officer)		March 29,2021
Nima Farzan
/s/ Mark Meltz		Chief Operating Officer and General Counsel (Principal Financial and Accounting Officer)		March 29,2021
Mark Meltz
/s/ Dean Mitchell		Chair of the Board of Directors		March 29,2021
Dean Mitchell
/s/ Melissa Epperly		Director		March 29,2021
Melissa Epperly
/s/ Keith Flaherty		Director		March 29,2021
Keith Flaherty, M.D.
/s/ Carl Gordon		Director		March 29,2021
Carl Gordon, Ph.D.
/s/ Stephen Kaldor		Director		March 29,2021
Stephen Kaldor, Ph. D.
/s/ Michael Rome		Director		March 29,2021
Michael Rome, Ph.D.
/s/ Laurie Smaldone Alsup		Director		March 29,2021
Laurie Smaldone Alsup, M.D.
/s/ Jim Tananbaum		Director		March 29,2021
Jim Tananbaum, M.D.